BioNTech Shares Surge on Groundbreaking Cancer Therapy Success

BioNTech SE has achieved a significant milestone in its oncology pipeline, sending its stock price sharply higher. The Mainz-based biotechnology company announced that its experimental cancer treatment successfully met the primary endpoint in a pivotal Phase 3 clinical trial, marking the company’s first late-stage success beyond its COVID-19 vaccine achievements.

The breakthrough centers on trastuzumab pamirtecan (BNT323/DB-1303), an antibody-drug conjugate developed in collaboration with partner Duality Biologics. The drug candidate demonstrated statistically significant improvement in progression-free survival for patients with HER2-positive, inoperable or metastatic breast cancer during an interim analysis.

BioNTech maintains global commercial rights for the therapeutic asset, excluding mainland China, Hong Kong, and Macau, where development and commercialization responsibilities remain with Duality Biologics. The company Read more...